230 related articles for article (PubMed ID: 38542509)
1. Identification of an Intravenous Injectable NK1 Receptor Antagonist for Use in Traumatic Brain Injury.
Vink R; Nimmo A
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542509
[TBL] [Abstract][Full Text] [Related]
2. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.
Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C
Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954
[TBL] [Abstract][Full Text] [Related]
3. Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors.
Harford-Wright E; Lewis KM; Ghabriel MN; Vink R
PLoS One; 2014; 9(5):e97002. PubMed ID: 24818961
[TBL] [Abstract][Full Text] [Related]
4. NK1 receptor blockade is ineffective in improving outcome following a balloon compression model of spinal cord injury.
Leonard AV; Thornton E; Vink R
PLoS One; 2014; 9(5):e98364. PubMed ID: 24859234
[TBL] [Abstract][Full Text] [Related]
5. The Role of Neurogenic Inflammation in Blood-Brain Barrier Disruption and Development of Cerebral Oedema Following Acute Central Nervous System (CNS) Injury.
Sorby-Adams AJ; Marcoionni AM; Dempsey ER; Woenig JA; Turner RJ
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28817088
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists.
Rupniak NM; Tattersall FD; Williams AR; Rycroft W; Carlson EJ; Cascieri MA; Sadowski S; Ber E; Hale JJ; Mills SG; MacCoss M; Seward E; Huscroft I; Owen S; Swain CJ; Hill RG; Hargreaves RJ
Eur J Pharmacol; 1997 May; 326(2-3):201-9. PubMed ID: 9196273
[TBL] [Abstract][Full Text] [Related]
7. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
Di Fabio R; Alvaro G; Braggio S; Carletti R; Gerrard PA; Griffante C; Marchioro C; Pozzan A; Melotto S; Poffe A; Piccoli L; Ratti E; Tranquillini E; Trower M; Spada S; Corsi M
Bioorg Med Chem; 2013 Nov; 21(21):6264-73. PubMed ID: 24075145
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist.
Ballard TM; Sänger S; Higgins GA
Eur J Pharmacol; 2001 Feb; 412(3):255-64. PubMed ID: 11166289
[TBL] [Abstract][Full Text] [Related]
9. Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists.
Darmani NA; Wang Y; Abad J; Ray AP; Thrush GR; Ramirez J
Brain Res; 2008 Jun; 1214():58-72. PubMed ID: 18471804
[TBL] [Abstract][Full Text] [Related]
10. NK1 antagonists attenuate tau phosphorylation after blast and repeated concussive injury.
Corrigan F; Cernak I; McAteer K; Hellewell SC; Rosenfeld JV; Turner RJ; Vink R
Sci Rep; 2021 Apr; 11(1):8861. PubMed ID: 33893374
[TBL] [Abstract][Full Text] [Related]
11. The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret.
Singh L; Field MJ; Hughes J; Kuo BS; Suman-Chauhan N; Tuladhar BR; Wright DS; Naylor RJ
Eur J Pharmacol; 1997 Feb; 321(2):209-16. PubMed ID: 9063690
[TBL] [Abstract][Full Text] [Related]
12. NK1 tachykinin receptor treatment is superior to capsaicin pre-treatment in improving functional outcome following acute ischemic stroke.
Turner RJ; Vink R
Neuropeptides; 2014 Oct; 48(5):267-72. PubMed ID: 25151181
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist.
Cascieri MA; Ber E; Fong TM; Hale JJ; Tang F; Shiao LL; Mills SG; MacCoss M; Sadowski S; Tota MR; Strader CD
Eur J Pharmacol; 1997 May; 325(2-3):253-61. PubMed ID: 9163573
[TBL] [Abstract][Full Text] [Related]
14. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice.
Teixeira RM; Santos AR; Ribeiro SJ; Calixto JB; Rae GA; De Lima TC
Eur J Pharmacol; 1996 Sep; 311(1):7-14. PubMed ID: 8884230
[TBL] [Abstract][Full Text] [Related]
15. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.
Beattie DT; Beresford IJ; Connor HE; Marshall FH; Hawcock AB; Hagan RM; Bowers J; Birch PJ; Ward P
Br J Pharmacol; 1995 Dec; 116(8):3149-57. PubMed ID: 8719789
[TBL] [Abstract][Full Text] [Related]
16. The tachykinin NK1 receptor in the brain: pharmacology and putative functions.
Saria A
Eur J Pharmacol; 1999 Jun; 375(1-3):51-60. PubMed ID: 10443564
[TBL] [Abstract][Full Text] [Related]
17. Increased blocking activity of combined tachykinin NK1- and NK2-receptor antagonists on tachykinergic bronchomotor responses in the guinea-pig.
Corboz MR; Fernandez X; Rizzo CA; Tozzi S; Monahan ME; Hey JA
Auton Autacoid Pharmacol; 2003 Feb; 23(1):79-93. PubMed ID: 14565542
[TBL] [Abstract][Full Text] [Related]
18. Magnesium enhances the beneficial effects of NK1 antagonist administration on blood-brain barrier permeability and motor outcome after traumatic brain injury.
Ameliorate JL; Ghabriel MN; Vink R
Magnes Res; 2017 Aug; 30(3):88-97. PubMed ID: 29256408
[TBL] [Abstract][Full Text] [Related]
19. Lack of evidence for tachykinin NK1 receptor-mediated neutrophil accumulation in the rat cutaneous microvasculature by thermal injury.
Pintér E; Brown B; Hoult JR; Brain SD
Eur J Pharmacol; 1999 Mar; 369(1):91-8. PubMed ID: 10204686
[TBL] [Abstract][Full Text] [Related]
20. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
